Clinical Trial Update: PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction [Phase 2]

View source ↗

Summary

Phase 2 trial investigating PDE5 inhibition for obesity-related cardiometabolic dysfunction has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiometabolic Dysfunction
• Healthy Individuals
• Obesity

Snippet

Sponsor: Vanderbilt University Medical Center | Conditions: Healthy, Obese | Phase 2 | Status: COMPLETED | Results posted: 2022-05-27